ArticleInternational journal of cardiology. Cardiovascular risk and prevention2025
Metabolites and coronary heart disease: A two sample Mendelian randomization.
Article in International journal of cardiology. Cardiovascular risk and prevention, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Advances in Metabolomics: A Comprehensive Review of Type 2 Diabetes and Cardiovascular Disease Interactions.International journal of molecular sciences · 2025Review
- Association between the TyGBS index and all-cause and cardiovascular mortality in diabetic stroke patients.Frontiers in endocrinology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In observational studies, circulating metabolites were related to Coronary heart disease (CHD), but their causal relationship is unknown. In this study, we sought to determine a bidirectional causal relationship between circulating metabolites and CHD and to explore whether circulating metabolites are associated with a decreased risk of CHD. Methods: In our two-sample Mendelian randomization (MR) study, the top SNPs associated with circulating metabolites (n = 24, 925) as well as CHD (n = 86, 995) were acquired from publicly available genome-wide association studies (GWAS). The SNPs estimates were pooled using inverse variance weighted meta-analysis, with median weighted by sensitivity analyses, MR Egger and MR Pleiotropy Residual Sum and Outlier (PRESSO). Results: Free cholesterol in large LDL(p, 6.9E-07; OR, 2.2; 95%CI,1.6-3.0),total cholesterol in medium LDL(p, 1.0E-06; OR, 1.8; 95%CI,1.4-2.3)Total cholesterol in LDL (p,1.43083E-05; OR,1.7; 95%CI, 1.3-2.2). Phospholipids in medium LDL (p,0.0; OR,1.6; 95%CI, 1.2-2.1); Total cholesterol in small VLDL (p,0.0; OR, 1.8; 95%CI, 1.2-2.7); Triglycerides in small VLDL (p,0.0, OR, 1.3; 95%CI, 1.0-1.6); Free cholesterol in small VLDL (p,0.0; OR,1.3; 95%CI, 1.0-1.7); Phospholipids in small VLDL (p,0.0; OR,1.3, 95%CI,1.0-1.7); Triglycerides in small HDL (p,0.0, OR,1.3,95%CI,1.0-1.7); Alanine (0.0, OR,1.2,95%CI,1.0-1.6) were positively associated with CHD. Phospholipids in medium HDL (p,0.0, OR,0.8; 95%CI, 0.6-0.9) might have a protective effect on CHD, which were negatively associated with CHD. Conclusions: Our MR analysis demonstrated a protective effect of Phospholipids in medium HDL, and a potentially anti-protective effect of Free cholesterol in large LDL, Total cholesterol in medium LDL, Total cholesterol in LDL, Phospholipids in medium LDL, Total cholesterol in small VLDL, Triglycerides in small VLDL, Free cholesterol in small VLDL, Phospholipids in small VLDL, Triglycerides in small HDL, Alanine on the pathogenesis of CHD. Additional studies are required to translate the findings into practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.